10-Q: NRC Health Q1 2026 Earnings: Revenue Up, Profit Down

NRC Health reported a 4% increase in Q1 2026 revenue to $34.8 million, but operating income fell 35% to $5.6 million due to increased expenses.

Summary

• Revenue for the first quarter of 2026 increased by 4% to $34.8 million, up from $33.6 million in the same period of 2025.
• This revenue growth was driven by $0.6 million in higher recurring revenue from existing customers and $0.5 million from new customers.
• Operating income decreased by 35% to $5.6 million in Q1 2026, compared to $8.6 million in Q1 2025.
• The decrease in operating income is attributed to a 30% increase in selling, general, and administrative (SG&A) expenses, largely due to higher stock-based compensation and executive salary expenses.
• Direct expenses rose by 5% to $13.6 million, primarily due to increased third-party software subscription costs and IT contractor services.
• Depreciation and amortization expenses increased by 41% due to the completion of headquarters renovations.
• Net income for the quarter was $3.2 million, down from $5.8 million in the prior year's quarter.
• Basic and diluted earnings per share were $0.14 for Q1 2026, compared to $0.25 for Q1 2025.
• Total Recurring Contract Value (TRCV) increased by 13% to $152.1 million, indicating a positive trend for future revenue.
• Cash provided by operating activities increased by 8% to $7.2 million.
• The company repurchased 109,701 shares of common stock for $1.9 million during the quarter under its new $60 million repurchase program.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While revenue and TRCV show positive growth, the significant decrease in operating income and net income due to rising expenses indicates a worsening profitability trend for the current period.

Positives

• Revenue increased by 4% to $34.8 million in Q1 2026.
• Total Recurring Contract Value (TRCV) grew by 13% to $152.1 million, signaling future revenue potential.
• Cash provided by operating activities increased by 8% to $7.2 million.
• The company has $2.5 million in cash and cash equivalents, with up to $30.0 million available under its Revolving Loan and an additional $27.6 million on its Delayed Draw Term Loan.
• The company remains in compliance with its financial covenants under its credit agreement.

Negatives

• Operating income decreased by 35% to $5.6 million in Q1 2026.
• Net income decreased to $3.2 million from $5.8 million in the prior year's quarter.
• Earnings per share (EPS) decreased to $0.14 from $0.25.
• Selling, general, and administrative expenses increased by 30% to $13.4 million.
• Depreciation and amortization expenses increased by 41%.

Risks

• Possibility of non-renewal of customer service contracts, reductions in services purchased or prices, and failure to retain key customers.
• Ability to compete in highly competitive markets with new entrants and consolidation among existing competitors, potentially leading to increased price pressure and expenses.
• Solutions and technology may not perform as expected.
• Acquisitions and partnerships may not achieve expected demand/profitability.
• Adverse effects of pandemics on operations, sales, earnings, financial condition, and liquidity.
• Adverse effects of global conflicts or tariffs on operations, sales, earnings, financial condition, and liquidity.
• Effects of an economic downturn.
• Impact of consolidation in the healthcare industry.
• Impact of federal healthcare and budget legislation, executive orders, cost-saving measures, and other regulatory changes.
• Ability to attract and retain key managers and other personnel.
• Potential for intellectual property and proprietary information technology to be copied or independently developed by competitors.
• Ability to maintain effective internal controls.
• Possibility of failures or deficiencies in the information technology platform.
• Potential for cyber-attacks, security breaches, or computer viruses affecting the company or its third-party providers.
• Factors set forth in the company's Annual Report on Form 10-K, as updated by subsequent filings.

Future Outlook

The company's future outlook is influenced by its ability to grow TRCV, which is seen as a leading indicator of future revenue. However, a significant expense increase is anticipated in Q2 2026 due to amendments to executive equity awards and related bonuses, expected to result in approximately $9.4 million of expense, impacting the effective tax rate for the remainder of 2026.

Management Comments

• Our commitment to Human Understanding helps leading healthcare systems improve their operations through understanding each person they serve not as point-in-time insights, but as an ongoing relationship.
• Our end-to-end solutions enable our customers to understand what matters most to each person they serve before, during, after, and beyond clinical encounters to gain a longitudinal understanding of how life and health intersect, with the goal of developing lasting, trusting relationships.
• We believe access to, analysis of, and acting on our extensive individual-driven information is increasingly valuable as healthcare providers need to better understand and engage the people they serve to create long-term relationships, build loyalty, and improve processes.
• We view TRCV as a leading indicator of our future revenue trends.

Industry Context

StockSavvy.ai notes that NRC Health's focus on 'Human Understanding' and longitudinal patient relationships aligns with the broader healthcare industry trend towards value-based care and patient-centric models. The company's cross-continuum positioning is a strategic advantage in an increasingly integrated healthcare landscape.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks or named competitors for the reported financial metrics.
• The company operates as a single segment, making direct segment-level comparisons challenging without further disclosure.

Corporate Governance

Legal Proceedings

• From time to time, the company is involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss and recognizes a liability when a loss is probable and estimable. No material changes from those disclosed in the Form 10-K.

Stakeholder Impact

• Shareholders: Decreased EPS and net income may negatively impact shareholder returns in the short term, though revenue growth and TRCV increase offer long-term potential. The new stock repurchase program may provide some support.
• Employees: Increased SG&A expenses include higher stock-based compensation and executive salary expenses, potentially indicating increased compensation for management.
• Customers: The company's focus on 'Human Understanding' and longitudinal relationships aims to improve customer outcomes and loyalty.
• Creditors: The company remains in compliance with its debt covenants, indicating continued financial stability from a credit perspective.

Next Steps

• The company will continue to focus on its 'Human Understanding' solutions to build lasting relationships with healthcare providers.
• The company will manage the expected $9.4 million expense in Q2 2026 related to executive equity award amendments and bonuses.
• The company will continue to monitor and comply with financial covenants under its credit agreement.
• The company may continue to repurchase shares under its $60 million stock repurchase program through March 31, 2028.

Key Dates

Recommendation

The company shows revenue growth and a strong TRCV, indicating future potential. However, the significant decline in operating income and net income due to increased expenses, particularly SG&A and executive compensation, raises concerns about current profitability. The upcoming Q2 expense related to executive equity amendments further clouds the near-term outlook. A 'hold' recommendation is appropriate given the mixed signals of growth versus declining profitability.

Keywords

NRC Health, 10-Q, Quarterly Report, Healthcare Technology, Patient Experience, Employee Engagement, Revenue Growth, Operating Income, Earnings Per Share, Financial Statements, SEC Filing